Event

Prevention and Management of Infusion Reactions (22EL-758)

Please note: AABB reserves the right to make updates to this program.

Wednesday, July 27, 2022
2:00 – 3:00 PM Eastern Time
Program Number: 22EL-758

  • Educational Track: Technical/Clinical
  • Topic: Cellular Therapy
  • Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Intermediate
  • Director/Moderator: Thomas R. Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
    Speakers:

    • Thomas R. Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
    • Kevin Land, MD, Vice President Clinical Services, Vitalant, San Antonio, TX
  • Program Description

    Reactions to cellular infusions are increasingly common, given the rapidly expanding arsenal of cellular products that are available to treat cancer and other diseases. This program will discuss the range of those reactions, spanning the spectrum from the consequences of infusing ABO incompatible progenitor cell products to reactions from components of the product preparation. Strategies for minimizing those reactions and treating them if they occur will be reviewed. Optimal reporting practices and grading of infusion reactions will also be discussed.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Identify the causes of cellular infusion reactions.
    • Describe the spectrum of reactions to cellular infusions.
    • Discuss management strategies for infusion reactions.
    • Review optimal reporting practices for infusion reactions.

    Registration

    Registration includes access to both the live and on-demand version of this eCast.

    If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team approximately one week prior to the live program (each team member to register for the program utilizing a promocode). For single viewers, simply click on the Register button below to register.

    Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time you will receive access to the on-demand eCast when it is available.

    Single Viewer Register
    Group Viewing Register

    Continuing Education Credit

    AABB estimates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

    Speaker Biographies

    Dr. Kevin Land Dr. Kevin Land is the Vice President of Clinical Services at Vitalant, supporting all hospital-facing services, including Reference Lab and Transfusion Services, Biotherapies (Cellular Therapy and Cord Blood Manufacturing), Therapeutic Apheresis and HPC collections, HLA, Hematology & Coagulation, and product manufacturing for research. He is also the Medical Director for the Cellular Therapy Laboratory in Tempe, Arizona and oversees the Vitalant Medical and Laboratory Directors.

    Dr. Land is a Clinical Pathologist who specializes in Cellular Therapy, Transfusion Medicine, and Informatics and has focused much of his career on Improving donor and patient outcomes, multi-center standardization, and laboratory management. Dr. Land is very active at the national and international levels, most recently serving as chair of ISBTs Haemovigilance Working Groups and as board member of the International Haemovigilance Network. His current focus is on Biotherapies and is active in the Cellular Therapies Section of AABB as a member of the Cell Therapy Subgroup Steering.

    Dr. Land completed his pathology residency and transfusion medicine fellowship at UT Southwestern Medical School in Dallas and Medical Informatics training at Johns Hopkins. Between 2000 and 2007 he held a joint appointment at Carter BloodCare and the Department of Pathology at UT Southwestern Medical Center in Dallas, Tx as the Medical Director of Laboratory Services, and Informatics, respectively, before joining Bonfils Blood Center as their first Chief Medical and Scientific Officer. Dr. Land joined Vitalant (then Blood Systems) in June 2011.


    Dr. Thomas Spitzer Dr. Thomas Spitzer is Medical and Laboratory Director of the Cellular Therapy and Transplantation Laboratory and Emeritus Director of the Bone Marrow Transplant Program, at the Massachusetts General Hospital and is Professor of Medicine at Harvard Medical School. He is also Walter Bauer Firm Chief in the Department of Medicine.

    Dr. Spitzer received his Bachelor of Science degree in Biology from Bucknell University and his M.D. from the University of Rochester School of Medicine. He completed his internship and residency in Internal Medicine at New York Hospital-Cornell Medical Center and Memorial-Sloan Kettering Cancer Center, and his Hematology-Oncology fellowship at Case Western Reserve University. His primary research interests have included the development of novel strategies for performing hematopoietic cell transplants across HLA barriers for hematologic malignancies and for inducing specific tolerance for organ transplantation by performing combined bone marrow and kidney transplants. The cellular therapy lab that he directs has provided all the products for hematopoietic cell transplantation at MGH and is currently involved with many novel immune effector cellular therapy trials. He has assumed leadership roles in AABB, including serving as Chair of the Cellular Therapy Section Coordinating Committee and as a member of the Board of Directors. He is a devoted teacher of medical students and residents in his Firm Chief role, and he has been the recipient of teaching awards for his contributions to medical education.